Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Official Title

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Keywords

Lymphoma, Follicular, Follicular lymphoma, Grade 1-3a Follicular lymphoma, BMS-986369, CC-99282, Lymphoma, Prednisone, Cyclophosphamide, Bendamustine Hydrochloride, Rituximab, Doxorubicin, Liposomal doxorubicin, Vincristine, Golcadomide, Bendamustine, Rituximab + Chemotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis.
  • Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable.
  • Stage II to IV disease.
  • Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:.

    i) Bulky disease defined as:.

    A. A nodal or extra nodal (except spleen) mass > 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than >3 cm). ii) Presence of at least one of the following B symptoms:. A. Fever (>38°C) of unclear etiology. B. Night sweats. C. Weight loss greater than 10% within the prior 6 months. iii) Splenomegaly with inferior margin below the umbilical line. iv) Any one of the following cytopenia due to lymphoma:. A. Platelets <100,000 cells/mm3 (100 x 109/L). B. Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L). C. Hemoglobin < 10g/dL (6.25 mmol/L). v) Pleural or peritoneal serous effusion (irrespective of cell content) vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal)

You CAN'T join if...

  • Clinical evidence of transformed lymphoma by investigator assessment.
  • Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification.
  • Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Locations

  • Local Institution - 0035
    San Francisco California 94143 United States
  • Local Institution - 0111
    Henderson Nevada 89074 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Celgene
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT06425302
Phase
Phase 2 Lymphoma Research Study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated